ArticleBMC medicine2025

Correction: Phase 1b study of first-line fuzuloparib combined with modified FOLFIRINOX followed by fuzuloparib maintenance monotherapy in pancreatic adenocarcinoma.

Miaoyan Wei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.